摘要目的:探讨非小细胞肺癌患者血清白细胞相关免疫球蛋白样受体2（leukocyte-associated immunoglobulin-like receptor 2，LAIR2）表达及与细胞免疫功能的关系。方法:选取2016年4月至2017年4月于商丘市第一人民医院接受治疗的90例非小细胞肺癌患者为肺癌组，根据5年内患者是否死亡分为生存组和死亡组。另选取同期84例良性肺部肿块患者为对照组。采用流式细胞术检测外周血免疫细胞CD4 +、CD8 +及CD4 +/CD8 +水平；采用酶联免疫吸附（ELISA）法检测血清LAIR2水平，并以非小细胞肺癌患者血清LAIR2水平平均值为界，分为LAIR2低表达组和LAIR2高表达组；采用Pearson相关分析非小细胞肺癌患者血清LAIR2水平与免疫细胞水平的相关性；采用Kaplan-Meier曲线分析血清LAIR2水平与非小细胞肺癌患者5年生存率的关系；采用多因素COX回归分析影响非小细胞肺癌患者5年内死亡的因素。 结果:肺癌组血清LAIR2[（69.55±13.12）vs（20.64±7.13）ng/ml]水平显著高于对照组，CD4 +[（28.26±5.14）% vs（47.02±6.73）%]、CD8 +[（23.76±5.84）% vs（30.12±6.03）%]及CD4 +/CD8 +[（1.17±0.30）% vs（1.56±0.50）%]水平显著低于对照组（ P<0.05）。TNM分期III+IV期（77.32±13.09）ng/ml、组织低分化（78.14±13.26）ng/ml、淋巴结转移（79.02±13.81）ng/ml患者血清LAIR2水平显著高于TNM分期I+II期（64.37±12.89）ng/ml、组织中/高分化（64.32±12.73）ng/ml、无淋巴结转移（62.92±12.85）ng/ml（ P<0.05）。LAIR2高表达组CD4 +、CD8 +及CD4 +/CD8 +水平显著低于LAIR2低表达组（ P<0.05）。非小细胞肺癌患者血清LAIR2水平与CD4 +、CD8 +及CD4 +/CD8 +水平均呈负相关（ r=-0.510、-0.496、-0.494， P<0.05）。LAIR2高表达患者5年生存率低于LAIR2低表达患者5年生存率（ χ2=6.375， P<0.05）。LAIR2是非小细胞肺癌患者5年内死亡的独立危险因素（ P<0.05）。 结论:LAIR2在非小细胞肺癌患者血清中高表达，且其表达水平与细胞免疫功能及预后密切相关。

abstractsObjective:To investigate the relationship between serum leukocyte-associated immunoglobulin-like receptor 2 (LAIR2) expression and cellular immune function, prognosis in patients with non-small cell lung cancer.Methods:From April 2016 to April 2017, 90 patients with non-small cell lung cancer who were treated in Shangqiu first people’s Hospital were taken as the lung cancer group, and they were grouped into the survival group and the death group according to whether the patients died within 5 years. Another 84 patients with benign pulmonary mass were selected as the control group. The levels of CD4+[ (28.26±5.14) % vs (47.02±6.73) %], CD8+ [ (23.76±5.84) % vs (30.12±6.03) %] and CD4+/CD8+ [ (1.17±0.30) % vs (1.56±0.50) %] in peripheral blood immune cells were detected by flow cytometry; the serum LAIR2 level was detected by enzyme-linked immunosorbent assay (ELISA) , and the average serum LAIR2 level of patients with non-small cell lung cancer was applied as the boundary, and they were grouped into a low LAIR2 expression group and a LAIR2 high expression group; Pearson correlation was applied to analyze the correlation between serum LAIR2 level and immune cell level in patients with non-small cell lung cancer; Kaplan-Meier curve was applied to analyze the relationship between serum LAIR2 level and 5-year survival rate of patients with non-small cell lung cancer; and multivariate COX regression analysis was applied to analyze the factors affecting 5-year mortality in patients with non-small cell lung cancer.Results:The level of serum LAIR2 [ (69.55±13.12) ng/ml vs. (20.64±7.13) ng/ml] in the lung cancer group was significantly higher than that in the control group, and the levels of CD4 +, CD8 + and CD4+/CD8+ were significantly lower than those in the control group ( P<0.05) . The serum LAIR2 level in patients with TNM stage III+IV (77.32±13.09) ng/ml, poorly differentiated tissue (78.14±13.26) ng/ml, and lymph node metastasis (79.02±13.81) ng/ml was significantly higher than that in patients with TNM stage I+II (64.37±12.89) ng/ml, medium/well differentiated tissue (64.32±12.73) ng/ml, and no lymph node metastasis (62.92±12.85) ng/ml ( P<0.05) . The levels of CD4 +, CD8 + and CD4 +/CD8 + in the LAIR2 high expression group were significantly lower than those in the LAIR2 low expression group ( P<0.05) . Serum LAIR2 level in patients with non-small cell lung cancer was negatively correlated with CD4+, CD8+ and CD4+/CD8+ levels ( r=-0.510, -0.496, -0.494, P<0.05) . The 5-year survival rate of patients with high LAIR2 expression was lower than that of patients with low LAIR2 expression ( r=6.375, P<0.05) . LAIR2 was an independent risk factor for 5-year death in patients with non-small cell lung cancer ( P<0.05) . Conclusion:LAIR2 is highly expressed in serum of patients with non-small cell lung cancer, and its expression level is closely related to cellular immune function and prognosis.